Loading…
Swedish animal-health group providing veterinary diagnostics, specialty pharma and pet-care products, built through acquisitions.
Swedish animal-health group providing veterinary diagnostics, specialty pharma and pet-care products, built through acquisitions.
In one line: A smaller, roll-up version of IDEXX Laboratories/Zoetis.
Moat: narrow (installed base, customer qualification). Niche diagnostics/specialty products with vet-clinic relationships, in a market led by larger scaled players.
Headquarters: Stockholm, Sweden · Founded: 2021 · Employees: 1,300
Size Vimian (VIMIAN.ST) is a Sweden Health Care company (Biotechnology) with a market value of $2.26B, the 78th largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 42.00 on 6 Nov 2026.
Performance Over six months the shares gained 40.7%, against +7.0% for the median peer and +8.2% for the Sweden market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 8.0% over the last twelve months (peer median +10.7%); the operating margin is 19.2% (peer median -19.3%).
Valuation It trades at 37.5× forward earnings against a peer median of 94.1× (3rd cheapest of 6).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +44%, so the hurdle is -32 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.3 points below its cost of capital (7.2% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 5.09B | SEK 4.70B | SEK 4.29B | SEK 3.81B | SEK 2.99B |
| Revenue growth | — | +10% | +13% | +27% | — |
| Gross profit | SEK 977M | SEK 799M | SEK 690M | SEK 596M | SEK 570M |
| EBITDA | SEK 1.44B | SEK 1.22B | SEK 1.08B | SEK 963M | SEK 860M |
| Net income | SEK 428M | SEK 346M | SEK 212M | SEK 113M | -SEK 71.7M |
| Free cash flow | SEK 1.03B | SEK 1.07B | SEK 592M | -SEK 419M | SEK 207M |
| Capital expenditure | SEK 234M | SEK 167M | SEK 162M | SEK 171M | SEK 110M |
| Total debt | SEK 3.18B | SEK 2.58B | SEK 2.67B | SEK 3.49B | SEK 2.46B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Vimian VIMIAN.ST | $2.26B | +41% | +8% | 19% | 37.5× | 12.5% |
| Idexx Laboratories IDXX | $53.3B | +21% | +12% | 32% | 41.5× | 28.0% |
| Zoetis ZTS | $32.8B | -4% | +1% | 38% | 12.8× | -4.3% |
| Elanco Animal Health ELAN | $12.9B | +9% | +12% | 7% | 21.8× | 34.8% |
| Virbac VIRP.PA | $3.38B | +5% | +4% | 15% | 17.2× | 6.2% |
| Vetoquinol VETO.PA | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VIMIAN.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +20.2% | +1.3% | 5th highest of 21 |
| 6-month return | +40.7% | +7.0% | 5th highest of 21 |
| Distance from 52-week high | -1.8% | -28.5% | 3rd highest of 21 |
| Revenue growth (TTM) | +8.0% | +10.7% | 8th highest of 15 |
| Operating margin | 19.2% | -19.3% | 5th highest of 13 |
| Forward P/E | 37.5× | 94.1× | 3rd cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | 12.5% | 22.0% | 2nd least demanding of 5 |
| Growth delivered (Del g) | +44.5% | +16.8% | highest of 4 |
| Hurdle (Req g minus delivered) | -32.0 pp | +21.9 pp | 2nd least demanding of 4 |
| ROIC minus cost of capital | -0.3 pp | -11.0 pp | 5th highest of 12 |
| EV / EBITDA | 17.3× | n/a | — |
| Net debt / EBITDA | 1.8× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 37.5× | 12.5% | +44.5% |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | n/a | n/a | n/a |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | n/a | 18.7% | n/a |
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | n/a | n/a | n/a |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 19.7× | 5.1% | +41.4% |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.32B | -32% | -49% | 51% | 8.8× | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | n/a | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | n/a | n/a | n/a |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 142.2× | n/a | n/a |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 94.1× | 38.7% | +16.8% |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 119.7× | 25.3% | +3.4% |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $2.07B | +34% | +1,496% | -92% | n/a | n/a | n/a |
| Replimune REPL | United States | $2.05B | +547% | n/a | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $2.04B | -1% | n/a | n/a | n/a | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |